Landing on the Science and Technology Innovation Board, Rongchang Biotechnology has entered the "A+H" era

On March 22, Rongchang Bioscience and Technology Innovation Board IPO issued 54.

4263 million shares, the issue price was 48 yuan, the amount of funds raised was 2.

Reviews

The reason why pharmaceutical companies favor the "A+H" structure so much is that on the one hand, it improves financing capabilities, and on the other hand, it will accelerate the process of commercialization and internationalization of enterprises
.

Commercialization is the "touchstone" for testing the hard power of innovative pharmaceutical companies

Hansoh Pharma's innovative drug revenue will rise by 169% in 2021

On March 29, Hansoh Pharma announced its 2021 annual results
.

In 2021, revenue was 9.
935 billion yuan, a year-on-year increase of 14.
3%; profit was 2.

It is worth noting that Hansoh Pharmaceutical's innovative drug sales revenue in 2021 was 4.

202 billion yuan, a year-on-year increase of 168.

Reviews

The sharp rise in Hansoh Pharmaceutical's revenue is inseparable from the layout of the innovative drug field
.

Before 2021, Hansoh Pharma maintained an annual average rate of 1-3 new projects for innovative drug applications; after 2021, the group started the explosive application of new projects, declared 14 new drug projects in the same year, and 5 in the first half of the year.
There are 9 new project declarations in the second half of the year, which are still accelerating

Tengsheng Biopharma cooperates with Sinopharm to commercialize neutralizing antibody against COVID-19

On March 30, Tengsheng Boyao announced that its subsidiary Tengsheng Huachuang and Sinopharm Holding have reached a strategic cooperation, and the two parties will work together to promote the company's long-acting new crown monoclonal neutralizing antibody ambavirumab/romisevirumab The commercialization process of combination therapy in China, including drug storage, channel distribution, regional access and other innovative business cooperation, will jointly contribute to China's epidemic prevention and control
.

Reviews

Ambavirumab and romisevirumab are non-competitive novel severe acute respiratory infections obtained by Tengsheng Biopharmaceuticals in cooperation with Shenzhen Third People's Hospital and Tsinghua University from patients with novel coronavirus pneumonia (COVID-19) during the recovery period.

Monoclonal neutralizing antibodies against systemic syndrome virus 2 (SARS-CoV-2), specifically applying bioengineering techniques to reduce the risk of antibody-mediated dependent potentiation and prolong plasma half-life for longer therapeutic effects

Huawei entered the field of medical equipment, and 4 products received registration certificates

On March 28, Huawei held the 2021 annual report conference.

Guo Ping, Huawei's rotating chairman, said that it will continue to expand its wearable and sports health business

Reviews

The ECG (electrocardiogram function) that the smartwatch was originally equipped with can show whether the user's heart rate shows signs of atrial fibrillation or normal sinus rhythm
.

In the next two to three years, smart watches may also have breakthroughs in functions such as blood sugar and blood pressure, providing disease monitoring and management for more patients with heart failure and chronic diseases
.
In addition, areas such as maternal health monitoring and elderly care are also in urgent need of intelligent monitoring.
Wearable smart devices are most likely to achieve their expectations and become a carrier for realizing a series of functions
.

R & D trends

Pfizer's new crown oral drug Shenzhen small-scale clinical showed preliminary efficacy

A small-scale clinical study conducted by Professor Lu Hongzhou's team from the National Infectious Disease Clinical Research Center of Shenzhen Third People's Hospital on 24 patients with new crowns showed that 5 days after the use of the new crown oral drug Paxlovid (Nimatevir tablets/ritonavir tablets), The average nucleic acid Ct value of these patients-ORF gene Ct value increased from 19.
365 before medication to 35.
92 after 5 days of medication, which met the discharge standard, and N gene increased from 18.
46 before medication to 34.
22 after 5 days of medication, which was close to the discharge standard
.
Lu Hongzhou said that although the preliminary results show that the drug is effective, it is still necessary to continue research and expand the sample size to make the results more accurate
.

Reviews

Since March 15, Pfizer's new crown oral drug Paxlovid was included in the latest version of the new crown pneumonia diagnosis and treatment plan, and it has been put into clinical use in areas of China where there are clusters of cases
.
The efficacy of Paxlovid in Chinese patients has also attracted much attention
.
According to the ninth edition of the New Coronary Pneumonia Diagnosis and Treatment Protocol, Paxlovid indications are mainly used for adults with mild and common types within 5 days of onset and with high risk factors for progression to severe disease
.
However, judging from the current domestic infection situation, most patients do not need to take this drug
.
At present, the proportion of severe cases in China is relatively low, and the use of Paxlovid in various places is also relatively limited, mainly for ordinary patients
.

Germany's Merck's c-Met inhibitor declares for listing in China

On March 30, the CDE official website showed that the German Merck’s c-Met inhibitor tepotinib tablet (tepotinib) was declared for listing in China
.
Tepotinib, developed by Merck in Germany, inhibits oncogenic MET receptor signaling caused by mutations in the MET gene
.
The pivotal phase II VISION study evaluated the efficacy and safety of tepotinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with MET ex14 skipping mutations
.
The results of the study showed that the ORR of tepotinib was 43% in both treatment-naïve and treatment-experienced patients
.
The mDOR was 10.
8 months in treatment-naïve patients and 11.
1 months in treatment-experienced patients
.
67% of treatment-naive patients and 75% of treatment-experienced patients achieved sustained remission for more than 6 months; 30% of treatment-naïve patients and 50% of treatment-experienced patients achieved sustained remission for more than 9 months
.

Reviews

MET gene exon 14 (MET ex14) skipping mutations account for 3% to 4% of NSCLC cases
.
Patients with this aggressive form of lung cancer are usually elderly and have a poor prognosis
.
Targeted therapies that produce durable antitumor activity are urgently needed to improve the lives of patients with this challenging disease
.

Hengrui Medicine's camrelizumab at the European Lung Cancer Congress again

On March 31, Hengrui Medicine announced that at the ongoing 2022 European Lung Cancer Conference (2022 ELCC), Professor Zhou Caicun of Shanghai Pulmonary Hospital affiliated to Tongji University orally reported the latest overall survival (OS) data of the CameL-sq study
.
The report pointed out that the median OS of camrelizumab combined with chemotherapy group was as long as 27.
4 months, which was nearly 1 year longer than that of chemotherapy group (15.
5 months), and the 3-year OS rate was 42.
8%
.
Hengrui Medicine pointed out that the CameL-sq study has refreshed the current median OS record of the phase III randomized controlled trial of immunotherapy combined with chemotherapy in the treatment of advanced lung squamous cell carcinoma.
median OS and 3-year OS rate), bringing a new breakthrough in the field
.

Reviews

This is the CameL-sq study data, after the positive results of the primary endpoint of progression-free survival (PFS) were presented orally at the European Lung Cancer Congress last year
.
In 2021, based on the data of the CameL-sq study, camrelizumab was recommended by the Chinese Society of Clinical Oncology (CSCO) guidelines as the standard first-line treatment of driver gene-negative advanced lung squamous cell carcinoma with immunotherapy combined with chemotherapy, and was awarded the National Drug of China in December.
The regulatory agency (NMPA) approved the corresponding indication, that is, the combination of paclitaxel and carboplatin for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer
.